Evaluation of [18F]-FET-βAG-TOCA for the imaging of NETs

  • Research type

    Research Study

  • Full title

    Evaluation of [18F]fluoroethyl triazole labelled [Tyr3]Octreotate analogues for the imaging of neuroendocrine tumours.

  • IRAS ID

    126964

  • Contact name

    Rohini Sharma

  • Contact email

    r.sharma@imperial.ac.uk

  • Sponsor organisation

    Imperial College London and Imperial College London Healthcare NHS Trust

  • Eudract number

    2013-003152-20

  • ISRCTN Number

    n/a

  • Research summary

    The incidence and prevalence of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) has been increasing over the past three decades. NETs cells surface has protein strucuture called somatostatin receptors (SSTR)that are able to bind some compound called somatostatine analogues. This compounds can also be labelled with radioactive substances in order to be visualized with molecular imaging techniques.Labelling these analogues would permit to perform positron emission tomography (PET) clinical protocols which can improve patients management. Previous work by this group discovered a novel tracer called [18F]fluoroethyl triazole labelled [Tyr3]Octreotate analogue ([18F]-FET-βAG-TOCA) which is a fluorinated octreotide analogue. We propose to further develop [18F]-FET-βAG-TOCA clinically via a 2 stage trial design. The first initial study will include a small number of patients with NET that will undergo a dynamic PET scan protocol to assess the dosimetry and safety of the tracer and to establish the optimal time for imaging. Using these information we will elaborate an appropriate protocol for a whole body static PET scanning that will be used for the second part of the study which will involve a larger number of patients. We will then compare the diagnostic efficacy of [18F]-FET-βAG-TOCA PET/CT to [68Ga]-DOTATATE PET/CT in patients with a histological diagnosis of NET. These clinical studies will be used as the basis for future larger clinical trials to establish this tracer as the new clinical standard based on equivalent sensitivity and specificity but improved kinetics and handling, as well as ease of GMP manufacturing than the existing [68Ga]-DOTATATE PET/CT.

  • REC name

    Yorkshire & The Humber - Leeds East Research Ethics Committee

  • REC reference

    13/YH/0281

  • Date of REC Opinion

    23 Sep 2013

  • REC opinion

    Further Information Favourable Opinion